检索结果-南通市图书馆

异戊橡胶IR70在全钢载重子午线轮胎内衬层过渡层胶中的应用

在线全文

学校读者我要写书评

暂无评论

橡胶科技 2015年第4期13卷 24-27页

作者：袁德彬胡录伟夏科伟杨维建黄照力四川凯力威科技股份有限公司四川简阳641400

研究国产异戊橡胶IR70在全钢载重子午线轮胎内衬层过渡层胶中的应用。结果表明,在内衬层过渡层胶中用并用比30/70的IR70/天然橡胶(NR)并用胶替代全NR,同时减小增粘树脂用量,胶料物理性能变化不大,半成品表面粘性明显提高,胎坯外观合格... 详细信息

研究国产异戊橡胶IR70在全钢载重子午线轮胎内衬层过渡层胶中的应用。结果表明,在内衬层过渡层胶中用并用比30/70的IR70/天然橡胶(NR)并用胶替代全NR,同时减小增粘树脂用量,胶料物理性能变化不大,半成品表面粘性明显提高,胎坯外观合格率升高,轮胎耐久性能略有改善,生产成本降低。

关键词：异戊橡胶天然橡胶内衬层过渡胶全钢载重子午线轮胎

抗硫化返原剂WK-901在无内胎全钢子午线轮胎胎肩垫胶中的应用

在线全文

学校读者我要写书评

暂无评论

橡胶科技 2013年第6期11卷 31-35页

作者：唐德全胡录伟夏科伟袁德彬杨维建四川凯力威科技股份有限公司四川简阳641400

研究抗硫化返原剂WK-901在无内胎全钢子午线轮胎胎肩垫胶中的应用。结果表明,在无内胎全钢子午线轮胎胎肩垫胶中加入0.75份抗硫化返原剂WK-901,可明显减小胶料在150℃和180℃下的硫化返原率,改善胶料物理性能和耐热老化性能,降低生热,... 详细信息

研究抗硫化返原剂WK-901在无内胎全钢子午线轮胎胎肩垫胶中的应用。结果表明,在无内胎全钢子午线轮胎胎肩垫胶中加入0.75份抗硫化返原剂WK-901,可明显减小胶料在150℃和180℃下的硫化返原率,改善胶料物理性能和耐热老化性能,降低生热,提高成品轮胎的耐久性能,减少肩空缺陷。

关键词：抗硫化返原剂胎肩垫胶全钢子午线轮胎硫化返原率肩空

SBR在全钢载重子午线轮胎下三角胶中的应用

在线全文

学校读者我要写书评

暂无评论

橡胶科技 2013年第8期11卷 24-27页

作者：陈刚杨利伟胡录伟夏科伟杨维建袁德彬四川凯力威科技股份有限公司四川简阳641400

研究丁苯橡胶(SBR)在全钢载重子午线轮胎下三角胶中的应用。结果表明:将全钢载重子午线轮胎下三角胶中的生胶由NR调整为NR与SBR并用(并用比为80/20),并调整硫化体系,胶料的门尼焦烧时间、硫化速度和硬度变化不大,定伸应力略有提高,拉伸... 详细信息

研究丁苯橡胶(SBR)在全钢载重子午线轮胎下三角胶中的应用。结果表明:将全钢载重子午线轮胎下三角胶中的生胶由NR调整为NR与SBR并用(并用比为80/20),并调整硫化体系,胶料的门尼焦烧时间、硫化速度和硬度变化不大,定伸应力略有提高,拉伸强度及拉断伸长率略有降低,拉断永久变形减小,耐热老化性能和成品轮胎胎圈耐久性能相当,成本明显降低。

关键词：天然橡胶丁苯橡胶全钢载重子午线轮胎下三角胶胎圈并用胶

聚苯胺纳米纤维/还原氧化石墨烯复合吸波材料的制备与性能

在线全文

学校读者我要写书评

暂无评论

聊城大学学报（自然科学版） 2021年第6期34卷 43-49页

作者：袁宝国张德宾徐国芬何金迎夏池魏化震范治平山东非金属材料研究所特种材料研究室山东济南250031 聊城大学生物制药研究院山东聊城252059

通过全程超声波辅助以还原氧化石墨烯(RGO)为基底,以聚苯胺纳米纤维(PANI nanofibers)为附着层制备了聚苯胺纳米纤维/还原氧化石墨烯(PANI nanofibers/RGO)复合吸波材料。发现全程超声波辅助和原料加入次序是制备PANI nanofibers/RGO的... 详细信息

通过全程超声波辅助以还原氧化石墨烯(RGO)为基底,以聚苯胺纳米纤维(PANI nanofibers)为附着层制备了聚苯胺纳米纤维/还原氧化石墨烯(PANI nanofibers/RGO)复合吸波材料。发现全程超声波辅助和原料加入次序是制备PANI nanofibers/RGO的关键。采用FTIR、XRD、TEM和电磁参数分析等方法研究了PANI nanofibers/RGO的形貌结构、形成过程与吸波性能。结果表明,在频率为14.6 GHz时,PANI nanofibers/RGO的反射损耗(RL)为-17.1 dB,在-10.0 dB以下的频率范围为10.0 GHz-16.4 GHz。此外,相比较于PANI nanofibers-RGO(PANI nanofibers与RGO的机械混合),和amorphous PANI/RGO(在RGO表面原位生长无定形的PANI)材料来说,PANI nanofibers/RGO具有吸波频带宽、RL高等优点,是一种有潜在应用前景的微波吸收剂。

关键词：还原氧化石墨烯聚苯胺纳米纤维吸波性能

Bevacizumab biosimilar LY01008 compared with bevacizumab(Avastin)as first-line treatment for Chinese patients with unresectable,metastatic,or recurrent non-squamous non-small-cell lung cancer:A multicenter,randomized,double-blinded,phase Ⅲ trial

在线全文

学校读者我要写书评

暂无评论

Cancer Communications 2021年第9期41卷 889-903页

作者： Yuankai Shi Kaijian Lei Yuming Jia Bingqiang Ni Zhiyong He Minghong Bi Xicheng Wang Jianhua Shi Ming Zhou Qian Sun Guolei Wang Dongji Chen Yongqian Shu Lianke Liu Zhongliang Guo Yong Liu Junquan Yang Ke Wang Ke xiao LinWu Tienan Yi debin Sun Mafei Kang Tianjiang Ma Yimin Mao Jinsheng Shi Tiegang Tang Yan Wang Puyuan Xing Dongqing Lv Wangjun Liao Zhiguo Luo Bin Wang xiaohong Wu xiaoli Zhu Shuhua Han Qisen Guo Rongyu Liu Zhiwei Lu Jianyong Zhang Jian Fang Changlu Hu Yinghua Ji Guolong Liu Hong Lu Dedong Wu Junhong Zhang Shuyang Zhu Zheng Liu Wensheng Qiu Feng Ye Yan Yu Yanqiu Zhao Qinhong Zheng Jun Chen Zhanyu Pan Yiping Zhang Wenjuan Lian Bo Jiang Bo Qiu Guojun Zhang Hua Zhang Yanju Chen Yuan Chen Hongbing Duan Manxiang Li Shengming Liu Lijun Ma Hongming Pan xia Yuan Xueli Yuan Yulong Zheng Emei Gao Li Zhao Shumin Wang Can Wu Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted DrugsBeijing 100021P.R.China Department of Oncology Yibin Second People’s HospitalYibinSichuan 644000P.R.China Department of Oncology Liuzhou People’s HospitalLiuzhouGuangxi 545006P.R.China Department of Thoracic Oncology Fujian Provincial Cancer HospitalFuzhouFujian 350014P.R.China Oncology Department the First Affiliated Hospital of Bengbu Medical CollegeBengbuAnhui 233030P.R.China Department of Oncology the First Affiliated Hospital of Guangdong Pharmaceutical UniversityGuangzhouGuangdong 510030P.R.China Department of Internal medicine Linyi Cancer HospitalLinyiShandong 276002P.R.China Department of Thoracic Surgery the Affiliated Cancer Hospital of Guangzhou Medical UniversityGuangzhouGuangdong 510095P.R.China Department of Internal Medicine-Oncology/Department of thoracic oncology Henan Chest HospitalZhengzhouHenan 450003P.R.China The Second Department of Radiotherapy Wuwei Cancer Hospital of Gansu ProvinceWuweiGansu 730000P.R.China Department of Oncology the People’s Hospital of Jiangsu ProvinceNanjingJiangsu 210000P.R.China Respiratory Medicine Department Shanghai East HospitalShanghai 200120P.R.China The Second Department of Internal Medicine-Oncology Xuzhou Central HospitalXuzhouJiangsu 221009P.R.China Oncology Department Tangshan People’s HospitalTangshanHebei 063001P.R.China Respiratory Medicine Department West China Hospital of Sichuan UniversityChengduSichuan 610041P.R.China Thoracic Surgery the Second Affiliated Hospital of Shantou University Medical CollegeShantouGuangdong 515051P.R.China Internal Medicine-Oncology Hunan Cancer HospitalChangshaHunan 410013P.R.China Department of Oncology Xiangyang Central HospitalXiangyangHubei 441021P.R.China Respiratory Department Lishui Central HospitalLishuiZ

Background:Previous studies have demonstrated the preclinical pharmacological and toxicological consistency,and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab(Avastin).This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first-line treatment of Chinese patients with advanced or recurrent non-squamous non-small cell lung cancer(NSCLC).Methods:StageⅢB-ⅣNSCLC patients with evaluable lesions,good physical status,and adequate organ functions from 67 centers across China were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin(combined treatment)for 4-6 cycles,followed by maintenance monotherapy with LY01008 until disease progression,intolerable toxicity,or *** primary endpoint was objective response rate(ORR)in accordance with Response Evaluation Criteria in Solid Tumors(RECIST)version 1.1 confirmed by independent radiological review committees(IRRC).Secondary endpoints included disease control rate(DCR),duration of response(DoR),progression-free survival(PFS),overall survival(OS),and *** study was registered in Clinical ***(NCT03533127).Results:Between December 15^(th),2017,and May 15^(th),2019,a total of 649 patients were randomized to the LY01008(n=324)or Avastin(n=325)*** of September 25th,2019 for primary endpoint analysis,589 patients received ORR evaluation,with a median number of combined treatment cycles of 5(range 1-6)andmedian duration of treatment of 3.0(range 0.0-5.1)*** responseevaluable patients in the LY01008 and Avastin groups were 48.5% and 53.0%,*** stratified ORR ratio was 0.91(90%CI 0.80-1.04,within the prespecified equivalence margin of 0.75-1.33).Up to May 15^(th),2020,with a median follow-up of 13.6(range 0.8-28.4)months,no notable differences in DCR,median DoR,median PFS,median OS,and 1-year OS rate were observed between the LY010

关键词： anti-angiogenesis anti-VEGF monoclonal antibody avastin bevacizumab biosimilar nonsmall cell lung cancer LY01008 vascular endothelial growth factor

“课程思政”视域下科研渗透式实验教学模式初探

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

大学化学 2022年第12期37卷 104-110页

作者：薛庆旺徐树玲张远馥黄德宾李爱峰李霞王怀生聊城大学化学化工学院山东聊城252000 聊城市第一中学山东聊城252000

为响应教育部《高等学校课程思政建设指导纲要》推进课程思政建设的号召,彰显高校立德树人的根本价值理念,用好化学实验教学主渠道,提升课程思政教学与育人能力。本文以“BiVO_(4)纳米纤维制备及电化学性能表征”综合化学实验为“渠道”... 详细信息

为响应教育部《高等学校课程思政建设指导纲要》推进课程思政建设的号召,彰显高校立德树人的根本价值理念,用好化学实验教学主渠道,提升课程思政教学与育人能力。本文以“BiVO_(4)纳米纤维制备及电化学性能表征”综合化学实验为“渠道”,将思政元素巧妙融合灌入,构建一种新型的师生间“双向传输知识”综合实验教学模式。通过“科研渗透”方式将综合化学实验教学内容延伸到科研前沿领域,增加实验教学内容的广度和新颖性,激发学生的科研热情,增强学生对基础研究的热爱,夯实建设科技强国的根基。通过“解剖麻雀式”典型范例剖析,提炼综合化学实验中蕴含的德育元素,实现专业教学和德育融入无缝衔接,培养学生勇于探索和创新的思辨精神,增加学生的社会责任感,实现全方位育人。

关键词：课程思政科研渗透综合化学实验教研相长

维普期刊数据库博看期刊